The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Clinical Trials, Phase III

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clinical Trials, Phase III


High impact information on Clinical Trials, Phase III


Chemical compound and disease context of Clinical Trials, Phase III


Biological context of Clinical Trials, Phase III


Anatomical context of Clinical Trials, Phase III


Associations of Clinical Trials, Phase III with chemical compounds


Gene context of Clinical Trials, Phase III


Analytical, diagnostic and therapeutic context of Clinical Trials, Phase III


  1. Thrombotic thrombocytopenic purpura associated with clopidogrel. Bennett, C.L., Connors, J.M., Carwile, J.M., Moake, J.L., Bell, W.R., Tarantolo, S.R., McCarthy, L.J., Sarode, R., Hatfield, A.J., Feldman, M.D., Davidson, C.J., Tsai, H.M. N. Engl. J. Med. (2000) [Pubmed]
  2. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Sartorius, C.A., Groshong, S.D., Miller, L.A., Powell, R.L., Tung, L., Takimoto, G.S., Horwitz, K.B. Cancer Res. (1994) [Pubmed]
  3. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Siim, B.G., Pruijn, F.B., Sturman, J.R., Hogg, A., Hay, M.P., Brown, J.M., Wilson, W.R. Cancer Res. (2004) [Pubmed]
  4. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Filippi, M., Horsfield, M.A., Adèr, H.J., Barkhof, F., Bruzzi, P., Evans, A., Frank, J.A., Grossman, R.I., McFarland, H.F., Molyneux, P., Paty, D.W., Simon, J., Tofts, P.S., Wolinsky, J.S., Miller, D.H. Ann. Neurol. (1998) [Pubmed]
  5. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Cummins, M.J., Papas, A., Kammer, G.M., Fox, P.C. Arthritis Rheum. (2003) [Pubmed]
  6. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Mahadevan, D., List, A.F. Blood (2004) [Pubmed]
  7. An introduction to nucleoside and nucleotide analogues. Squires, K.E. Antivir. Ther. (Lond.) (2001) [Pubmed]
  8. Aptamers: an emerging class of therapeutics. Nimjee, S.M., Rusconi, C.P., Sullenger, B.A. Annu. Rev. Med. (2005) [Pubmed]
  9. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Schiller, J.H., Kim, K., Hutson, P., DeVore, R., Glick, J., Stewart, J., Johnson, D. J. Clin. Oncol. (1996) [Pubmed]
  10. Role of glutathione in the hypoxic cell cytotoxicity of misonidazole. Bump, E.A., Taylor, Y.C., Brown, J.M. Cancer Res. (1983) [Pubmed]
  11. Safety of flurbiprofen in the treatment of ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. A summary of liver and kidney assay data. Lomen, P.L., Turner, L.F., Lamborn, K.R. Am. J. Med. (1986) [Pubmed]
  12. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Mulato, A.S., Lamy, P.D., Miller, M.D., Li, W.X., Anton, K.E., Hellmann, N.S., Cherrington, J.M. Antimicrob. Agents Chemother. (1998) [Pubmed]
  13. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Hu, R., Li, L., Degrève, B., Dutschman, G.E., Lam, W., Cheng, Y.C. Antimicrob. Agents Chemother. (2005) [Pubmed]
  14. The anticonvulsant effects of the enantiomers of losigamone. Jones, F.A., Davies, J.A. Br. J. Pharmacol. (1999) [Pubmed]
  15. New options for outpatient chemotherapy--the role of oral fluoropyrimidines. Cunningham, D., Coleman, R. Cancer Treat. Rev. (2001) [Pubmed]
  16. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Moore, K.H., Yuen, G.J., Hussey, E.K., Pakes, G.E., Eron, J.J., Bartlett, J.A. Antimicrob. Agents Chemother. (1999) [Pubmed]
  17. Pharmacokinetics and tolerability of extended-release clarithromycin. Guay, D.R., Gustavson, L.E., Devcich, K.J., Zhang, J., Cao, G., Olson, C.A. Clinical therapeutics. (2001) [Pubmed]
  18. Radiosensitizer sanazole (AK-2123) enhances gamma-radiation-induced apoptosis in murine fibrosarcoma. Rajagopalan, R., Kagiya, T.V., Nair, C.K. J. Radiat. Res. (2003) [Pubmed]
  19. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Tölle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schönfelder, G., Schäfers, M., von Wnuck Lipinski, K., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., Van der Giet, M. Circ. Res. (2005) [Pubmed]
  20. Tesaglitazar: A promising approach in type 2 diabetes. Cox, S.L. Drugs of today (Barcelona, Spain : 1998) (2006) [Pubmed]
  21. G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation. Juan, G., Ardelt, B., Li, X., Mikulski, S.M., Shogen, K., Ardelt, W., Mittelman, A., Darzynkiewicz, Z. Leukemia (1998) [Pubmed]
  22. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Crawford, J. Semin. Oncol. (2003) [Pubmed]
  23. Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Hall, E.D., Andrus, P.K., Smith, S.L., Oostveen, J.A., Scherch, H.M., Lutzke, B.S., Raub, T.J., Sawada, G.A., Palmer, J.R., Banitt, L.S., Tustin, J.S., Belonga, K.L., Ayer, D.E., Bundy, G.L. Acta Neurochir. Suppl. (1996) [Pubmed]
  24. 2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2+ bound to a dodecamer DNA duplex. Silverman, A.P., Bu, W., Cohen, S.M., Lippard, S.J. J. Biol. Chem. (2002) [Pubmed]
  25. The next generation of PDE4 inhibitors. Huang, Z., Ducharme, Y., Macdonald, D., Robichaud, A. Current opinion in chemical biology. (2001) [Pubmed]
  26. Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. Coplan, P.M., Nikas, A.A., Leavitt, R.Y., Doll, L., Nessly, M.L., DiNubile, M.J., Guess, H.A. AIDS (2001) [Pubmed]
  27. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Cracowski, J.L., Girolet, S., Imbert, B., Seinturier, C., Stanke-Labesque, F., Bessard, J., Boignard, A., Bessard, G., Carpentier, P.H. Free Radic. Biol. Med. (2005) [Pubmed]
  28. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma. Benimetskaya, L., Wittenberger, T., Stein, C.A., Hofmann, H.P., Weller, C., Lai, J.C., Miller, P., Gekeler, V. Clin. Cancer Res. (2004) [Pubmed]
  29. Cytotoxicity of bovine seminal ribonuclease: monomer versus dimer. Lee, J.E., Raines, R.T. Biochemistry (2005) [Pubmed]
  30. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Fiorucci, S., Meli, R., Bucci, M., Cirino, G. Biochem. Pharmacol. (2001) [Pubmed]
  31. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Lee, L., Sharma, S., Morgan, B., Allegrini, P., Schnell, C., Brueggen, J., Cozens, R., Horsfield, M., Guenther, C., Steward, W.P., Drevs, J., Lebwohl, D., Wood, J., McSheehy, P.M. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  32. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Buzdar, A.U., Vergote, I., Sainsbury, R. The breast journal. (2004) [Pubmed]
  33. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Reshkin, S.J., Bellizzi, A., Cardone, R.A., Tommasino, M., Casavola, V., Paradiso, A. Clin. Cancer Res. (2003) [Pubmed]
  34. RNA cleavage and inhibition of protein synthesis by bleomycin. Abraham, A.T., Lin, J.J., Newton, D.L., Rybak, S., Hecht, S.M. Chem. Biol. (2003) [Pubmed]
  35. Effects of increased lipid concentration and hyperemic blood flow on the intrinsic myocardial washout kinetics of (99m)TcN-NOET. Riou, L.M., Unger, S., Toufektsian, M.C., Ruiz, M., Watson, D.D., Beller, G.A., Glover, D.K. J. Nucl. Med. (2003) [Pubmed]
  36. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Bumgardner, G.L., Hardie, I., Johnson, R.W., Lin, A., Nashan, B., Pescovitz, M.D., Ramos, E., Vincenti, F. Transplantation (2001) [Pubmed]
  37. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit, R., Herrstedt, J., Rapoport, B., Carides, A.D., Guoguang-Ma, J., Elmer, M., Schmidt, C., Evans, J.K., Horgan, K.J. Eur. J. Cancer (2004) [Pubmed]
  38. Single-agent docetaxel (Taxotere) in randomized phase III trials. Burris, H.A. Semin. Oncol. (1999) [Pubmed]
WikiGenes - Universities